Rituximab treatment in hepatitis C infection: An in vitro model to study the impact of B cell depletion on virus infectivity

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Stamataki, Zania ^a   Tilakaratne, Samantha ^a   Adams, David H ^a   McKeating, Jane A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; VIRUS RNA; CD20 ANTIGEN; IMMUNOLOGIC FACTOR; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; VIRUS INFECTIVITY; VIRUS RELEASE; VIRUS REPLICATION; BIOLOGICAL MODEL; CHEMISTRY; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; NATURAL KILLER CELL; STATISTICAL MODEL; VIROLOGY;

HEPATITIS C VIRUS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; HEPATITIS C; HEPATOCYTES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; MODELS, STATISTICAL;

EID: 80053615524     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025789     Document Type: Article

References (18)

1. Hoofnagle JH, (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26: 15S-20S.
2. Galossi A, Guarisco R, Bellis L, Puoti C, (2007) Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis 16: 65-73.
3. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, et al. (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833.
5. Pescovitz MD, (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6: 859-866.
6. Uchida J, Lee Y, Hasegawa M, Liang Y, Bradney A, et al. (2004) Mouse CD20 expression and function. Int Immunol 16: 119-129.
7. Glennie MJ, French RR, Cragg MS, Taylor RP, (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-3837.
8. Cragg MS, Glennie MJ, (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103: 2738-2743.
9. Cartron G, Watier H, Golay J, Solal-Celigny P, (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104: 2635-2642.
10. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, et al. (2007) Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109: 845-846.
11. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, et al. (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101: 3818-3826.
12. Stamataki Z, (2010) Hepatitis C infection of B lymphocytes: more tools to address pending questions. Expert Rev Anti Infect Ther 8: 977-980.
13. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-626.
14. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
15. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294-9299.
16. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, et al. (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48: 1843-1850.
17. Stamataki Z, Shannon-Lowe C, Shaw J, Mutimer D, Rickinson AB, et al. (2009) Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 113: 585-593.
18. Alter G, Malenfant JM, Altfeld M, (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294: 15-22.